CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE

Flavio QUEIROZ-TELLES(1)

SUMMARY

Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM require long term therapy with systemic antifungals, sometimes associated with physical methods. Unlike other neglected endemic mycoses, comparative clinical trials have not been performed for this disease. Nowadays, therapy is based on a few open trials and on expert opinion. Itraconazole either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been successfully employed in combination with antifungals in patients presenting with CBM. In the present revision the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient’s outcome.

KEYWORDS: Chromoblastomycosis; Dematiaceous fungi; Fungal infections; Antifungal treatment.

INTRODUCTION

Neglected diseases constitute a group of tropical and subtropical infections which are endemic in low-income populations in developing regions of Africa, Asia, and Latin America. The World Health Organization (WHO) acknowledges the neglected diseases as a symptom of poverty and disadvantage. The most affected by the neglected diseases are the poorest populations often living in remote, rural areas, urban slums or in conflict zones. With little political support, neglected tropical diseases are not on the priority list of public health systems. A series of endemic diseases including helminths, protozoa, bacterial and viral infections, but not fungal diseases other than mycetoma are considered neglected diseases by WHO. Its global burden should be even greater than mycetoma and CBM can lead to potential incapacity for labor. The aim of this review is to update the main clinical, epidemiological and therapeutic topics on CBM, a typical orphan disease.

CHROMOBLASTOMYCOSIS

Chromoblastomycosis or chromomycosis is one of the most prevalent transcutaneous traumatic implantation or subcutaneous mycosis in individuals living in tropical and subtropical zones around the world. Although PEDROSO & GOMES observed some patients in 1910 in São Paulo, Brazil, the scientific report of these observations appeared only in 1920. This is the reason why the first description of CBM is actually attributed to Max RUDOLPH, a German doctor who published the first cases of CBM from the city of Estrela do Sul, Minas Gerais, Brazil, in 1914. This disease presents the following characteristics: primary lesion beginning at the site of inoculation; chronic involvement of cutaneous and subcutaneous tissues associated with a granulomatosus, purulent, fibrotic tissue formation and a non-protective humoral immune response. CBM lesions are usually recalcitrant and extremely difficult to eradicate. Due to its chronicity, CBM lesions may undergo neoplastic transformation leading to skin cancer. Except for small initial lesions that can be cured by surgical removal, CBM lesions constitute a true therapeutic challenge for clinicians and patients (Fig. 1).

Fig. 1 - Severe and recalcitrant clinical form of chromoblastomycosis.

(1) Universidade Federal do Paraná, Departamento de Saúde Pública, Curitiba, PR, Brasil. E-mail: queiroz.telles@uol.com.br
ECO-EPIDEMIOLOGY

Chromoblastomycosis is the most common of several mycoses caused by melanized or black fungi. CBM agents are found on soil, plant thorns and debris\(^{15,35}\). These fungi belong mainly to *Fonsecaea* and *Cladophialaphora* genus and, while scattered cases have been reported in *Phialophora*, *Rhinocladiella* and *Exophiala* genus. *F. pedrosoi* and *C. carrionii* are usually found in tropical and subtropical regions. *F. pedrosoi* is primarily found in humid areas, whereas *C. carrionii* is prevalent in semiarid climates\(^{11,23,24,34,38}\). As with other members of the Herpotrichiellaceae family, these agents have melanin in their cell wall, an important pathogenicity factor\(^{31}\). It is believed that CBM etiologic agents are soil and/or plant saprobes with typical mycelia in environmental samples, changing morphology to the muriform (sclerotic) form in tissue (Fig. 2)\(^{13,19}\).

The highest prevalence of the disease is within a zone between 30° latitude North and 30° latitude South, coinciding with most of the tropical and subtropical zones. CBM is not a compulsory reportable disease so that all epidemiology data is derived from published case reports and surveys. Incidence rates range from 1: 6,800 (14/100,000) in Madagascar to 1: 8,625,000 (0.012/100,000) in USA. In Brazil the estimate incidence rate of CBM is 3/100,000\(^{25}\). Most of the reported cases occur in Latin America, the Caribbean, Asia, Africa and Australia. Madagascar, Brazil, Mexico, Dominican Republic, Venezuela, India and Southern China contribute with the majority of cases (Fig. 3)\(^{3,11,16,17,23,25,29,34,38}\).

Chromoblastomycosis-causing fungi are found worldwide in soil and decaying plant debris, including wood. Because CBM is an implantation mycosis, occupation seems to play an important role\(^{1,24,25}\). This disease rarely occurs before adolescence with most patients in the age group between 40 to 50-years old, with a male-to-female ratio of 5:1 and 9:1\(^{1,24,25}\). The majority of lesions are observed on the extremities of outdoor rural workers. The main risk factors associated with CBM infection are: lack of protective shoes, gloves or garments, poor nutrition and hygienic habits\(^{1}\). CBM is considered an occupational disease, occurring in farm workers, lumberjacks, or vendors of farm products. A potentially important source of infection was reported in an endemic area located in the Maranhao State, on the fringes of the Amazon rainforest in Brazil, where thousands of families are involved in babassu (*Orbignya phalerata*) a wild palm tree, harvesting. The local population collects babassu nuts to extract the babassu oil, an important component for local and international beauty product manufacturers. Because melanized fungi have been isolated from babassu shield fragments, this may be a risk factor for hundreds of people developing CBM after trauma that occurred at work (Fig. 4)\(^{18,33}\). Other occupational hazards are likely in other environments (Table 1).

CLINICAL MANIFESTATIONS

Following a transcutaneous traumatic implantation, and after an uncertain incubation period, the initial CBM lesion appears at
verrucous lesion of the foot. These therapeutic modalities are only indicated at the tumoral stage. In advanced and severe cases, more than one type of treatment may be used concordantly or sequentially. The initial skin plaque lesion on the buttocks evolves with diverse clinical types including abscesses. Granulomatous reaction with different grades of fibrosis can be found at the dermal level. Muriform cells may be observed among these structures or inside Langerhans giant cells. When cultivated, all CBM agents grow slowly in culture.

As severity increases, edema and bacterial secondary infections affect the health of the patient as a whole, modifying the appearance of the skin and causing scars. In the most severe cases, chronic lymphedema and ankylosis develop and non-invasive squamous cell carcinomas may arise. All these complications can lead to definitive disability (Fig. 1).

**DIAGNOSIS**

Diagnosis of CBM is mainly based on clinical and epidemiological suspicion in endemic areas but it must be confirmed by microbiological demonstration of the etiologic agents in clinical samples. Skin biopsies or scrapings should be taken from the surface of the lesion where “black dots” may be visible. When examined under light microscopy the pathognomonic “muriform cells” are depicted. These chestnut, rounded brown pigmented and cross chambered structures are distinctive and have been referred to as “sclerotic bodies, fumagoid cells” cooper petals.Muriform cells are considered as a biological adaptation allowing the etiologic agent to survive in the hostile host tissue environment. Histologically, CBM typically reveals pseudo epitheliomatous epidermal hyperplasia, hyperkeratosis, irregular acanthosis, alternating with areas of atrophy and collection of inflammatory cells forming epidermic abscesses. Granulomatous reaction with different grades of fibrosis can be found at the dermal level. Muriform cells may be observed among these structures or inside Langerhans giant cells. When cultivated, all CBM agents grow slowly in culture. Initially, colonies are deep green, depicting a velvet dark aspect with time. Presumptive species identification may be achieved by mycological morphologic methods, but molecular techniques are suggested for definitive identification.

**THERAPY**

Chromoblastomycosis lesions are recalcitrant and very difficult to treat. If not discovered early when the initial CBM lesions may be surgically removed, long periods of systemic antifungal therapy alone or in combination with several physical methods is the rule for many patients. The efficacy of therapy may be related to the severity and duration of the disease, to the etiologic agent and to the patient’s compliance. As comparative trials on this disease are lacking, evidence that helps to select optimal therapy is based on a few open clinical studies and expert opinion. No “gold standard” therapy for CBM is available, but treatment options include systemic antifungals, as monotherapy or combined, physical methods and immune adjuvants (Table 2).

Over time, several therapeutic regimens have been tried, including physical methods such as surgery, thermo, laser and photodynamic therapies. These therapeutic modalities are only indicated at the early stages of the disease. They can also be associated with systemic antifungal therapy. Initially, mild CBM lesions can be treated by surgical excision but unfortunately most of the patients present with moderate
Orbignya. Thus, it is accepted that 14,26,27.

In refractory cases, 31 27 -

úngica crônica da pele e Martius) in the Amazon region of Maranhão, Brazil. Nihon Ishinkin Gakkai from the shell of babassu coconut (Combination therapy ;

Other effective drugs. In addition, neither

1. AL-DOORY Y. Chromomycosis. In: Di Salvo AF. Occupational mycoses. Philadelphia: Lea & Febiger; 1983. p. 95-121.

2. Antonello VS, Appel da Silva MC, Cambruzzi E, Klemmanna DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo. 2010;52:329-31.

3. Attappattu MC. Chromoblastomycosis: a clinical and mycological study of 71 cases from Sri Lanka. Mycopathologia. 1997;137:145-51.

4. Avelar-Pires C, Simoes-Quaresma JA, Moraes de Macedo GM, Brasil-Xavier M, Cardoso de Brito A. Revisiting the clinical and histopathological aspects of patients with chromoblastomycosis from the Brazilian Amazon region. Arch Med Res. 2013;44:302-6.

5. Bolzinger T, Pradinaud R, Sainte-Marie D, Dupont B, Chwetzoff E. Traitement de quatre cas de chromomycose à Fonsecaea pedrosoi par l’association 5-flucytosine-itraconazole. Nouv Dermatol. 1991;10:462-6.

6. Bonifaz A, Carrasco-Gerard E, Saul A. Chromomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44:1-7

7. Bonifaz A, Saul A, Paredes-Solis V, Araiza J, Fierro-Arias L. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat. 2005;16:47-51.

8. Carrion AL. Chromoblastomycosis. Ann NY Acad Sci. 1950;50:1255-82.

9. Castro RM, Castro LGM. On the priority of description chromomycosis. Mykosen. 1987;30:397-403.

10. De Hoog GS, Attiliani-Angelis D, Vicente V A, Van Den Ende AH, Queiroz-Telles F. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol. 2004;42:405-16.

11. Esterre P, Andriantsimahavandy A, Ramarcel ER, Pecarrere JL. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg. 1996;55:45-7.

12. Esterre P, Inzan CK, Ratsiharana M, Andriantsimahavandy A, Raharisolo C, Randrianainia E et al. Multicenter trial of terbinafine in patients with chromoblastomycosis: effects on clinical and biological criteria. J Dermatolog Treat. 1998;9(Suppl 1):S29-S34.

13. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19:148-52.

14. Garnica M, Nucci M, Queiroz-Telles F. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr Opin Infect Dis. 2009;22:559-63.

15. Gezuelle E, Mackinnon JE, Conti-Díaz IA. The frequent isolation of Phialophora verrucosa and Phialophora pedrosi from natural sources. Sabouraudia. 1972;10:266-73.

16. Leslie DF, Beardmore GL. Chromoblastomycosis in Queensland: a retrospective study of 13 cases at the Royal Brisbane Hospital. Australas J Dermatol. 1979;20:23-30.

17. Lu S, Lu C, Zhang J, Hu Y, Li X, Xi L. Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics. Mycopathologia. 2013;175:489-95.

18. Marques SG, Silva C de M, Saldanha PC, Resende MA, Vicente VA, Queiroz-Telles F. et al. Isolation of Fonsecaea pedrosoi from the shell of babassu coconut (Orbignya phalerata Martius) in the Amazon region of Maranhão, Brazil. Nihon Ishinkin Gakkai Zasshi. 2006;47:305-11.

REFERENCES

**Table 2**

| Physical methods | Chemotherapy | Combination therapy |
|------------------|--------------|---------------------|
| Standard surgery * | Calciferol (Vit D3) § | Itraconazole + cryotherapy ** |
| Iontophoresis † | 5-氟尿嘧啶 § | Terbinafine + cryotherapy ** |
| Moh’s surgery † | 5-氟尿嘧啶 § | Terbinafine ** |
| CO₂ laser † | Thiabendazole † | Itraconazole + terbinafine ** |
| Cryotherapy † | Amphotericin B † | Itraconazole + photodynamic therapy ** |
| Local heat (dry) † | Ketoconazole † | Itraconazole + 5-氟尿嘧啶 ** |
| Photodynamic therapy † | Fluconazole † | Itraconazole + 5-氟尿嘧啶 ** |
| | Itraconazole † | Terbinafine ‡ |
| | Posaconazole †† | Isavuconazole †† |

* For initial lesions only; **Used only in association to systemic antifungals; † Most used therapy; ‡ Use for refractory forms; ?? Potential use; § Not used or not a first line therapy or abandoned therapy.

...to severe forms, leading to long-term courses of systemic antifungal drugs. In addition, neither in vitro sensitivity tests are standard for the filamentous and the parasitic (muriform), nor experimental therapy models have been successfully developed. Thus, it is accepted that the most used drugs are itraconazole and terbinafine at daily doses of 200-400 mg and 250-500 mg, respectively11,12,26,27,28,30. In refractory cases, the combination of these two drugs can be employed22. Other effective treatments include posaconazole, 800 mg per day and the combination of itraconazole with 5-flucytosine13,14,21. The association of the latter with posaconazole may play an important role in the therapy of CBM. The duration of therapy must be based on clinical, mycological and histopathological criteria (Table 2). According to published data, cure rates with terbinafine or itraconazole vary from 15 to 80%, depending on the severity of the disease. As expected, in severe forms cure rates are lower and relapses are more common14,26,27.

**RESUMO**

Cromoblastomicose: doença tropical negligenciada

Cromoblastomicose (CBM) é uma infecção fungica crônica da pele e tecido subcutâneo causada pela inoculação transitória traumática de um grupo específico de fungos dermáticos que ocorrem principalmente em zonas tropicais e subtropicais do mundo. Quando não são diagnosticados nas fases iniciais, pacientes com CBM necessitam de tratamentos prolongados com antifúngicos sistêmicos, por vezes associados a métodos físicos. Diferentemente de outras micoses endêmicas negligenciadas, não foram realizados ensaios clínicos comparativos para esta doença. Atualmente a terapia é baseada em alguns poucos ensaios abertos e em opiniões de especialistas. Itraconazol é amplamente usado como monoterapia ou em associação com outras drogas, ou com métodos físicos. Recentemente, a terapia fotodinâmica foi empregada com sucesso combinada a antifúngicos em pacientes com CBM. Neste manuscrito as opções terapêuticas mais utilizadas contra CBM foram revistas, assim como os diversos factores que podem influenciar a evolução dos pacientes.
19. Matsumoto T, Matsuda T, McGinnis MR, Ajello L. Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses. 1993;36:145-55.

20. McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983;8:1-16.

21. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2005;47:339-46.

22. Pedroso A, Gomes JM. Sobre quatro casos de dermatite verrucosa produzida pela Phialophora verrucosa. Ann Paul Med Cirur. 1920;11:53-61.

23. Perez-Blanco M, Hernández Valles R, Garcia-Humbria L, Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the Falcon State, Venezuela. Med Mycol. 2006;44:467-71.

24. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3-15.

25. Queiroz-Telles F, Nucci M, Colombo AL, Tobón A, Restrepo A. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol. 2011;49:225-36.

26. Queiroz-Telles F, Purim KS, Filus JN, Bordignon GF, Laneira RP, Van Cutsem J, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31:805-12.

27. Queiroz-Telles F, Santos DWCL. Chromoblastomycosis in the clinical practice. Curr Fungal Infect Rep. 2012;6:312-9. doi: 10.1007/s12281-012-0116-8.

28. Queiroz-Telles F, Santos DW. Challenges in the therapy of chromoblastomycosis. Mycopathologia. 2013;175:477-88.

29. Rajendran C, Ramesh V, Misra RS, Kandhari S, Upreti HB, Datta KK. Chromoblastomycosis in India. Int J Dermatol. 1997;36:29-33.

30. Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988;544:504-16.

31. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev. 2010;23:884-928.

32. Rudolph M. Über die brasilianische “Figueira” (Vorläufige Mitteilung). Arch Schiffs Tropen-Hyg. 1914;18:498-9.

33. Silva ACCM, Serra Neto A, Galvão CES, Marques SG, Saldanha ACR, Silva CMP, et al. Chromoblastomycosis produced by Fonsecaea pedrosoi in the state of Maranhão, Brazil: Clinical, epidemiological and evolutivistic aspects. Rev Soc Bras Med Trop. 1992;25:37-44.

34. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998;143:171-5.

35. Tschern JA, Knox JM, McGavran MH, Duncan WC. Chromomycosis. The association of fungal elements and wood splinters. Arch Dermatol. 1984;120:107-8.

36. Van de Sande W, Maghoub el S, Fahal AH, Goodfellow M, Welsh O, Zijlstra E. The mycetoma knowledge gap: identification of research priorities. PLOS Negl Trop Dis. 2014;8:e2667.

37. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. Geneva: World Health Organization/Department of Control of Neglected Tropical Diseases; 2013.

38. Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the Falcon State, Venezuela. Med Mycol. 2006;44:467-71.